Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
The total cost of the project is estimated at Rs 30 crore
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
The company is focused on the development of novel treatments for RNA viruses
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
Working under the Ministry of Ayush, NMPB is mandated to coordinate all matters relating to medicinal plants and support policies and programs for growth of trade, export, conservation, and cultivation of medicinal plants
The hospital is scheduled to open in 2024 with a bed capacity of 225
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
One of the very few facilities in India to have this capability, marking a remarkable feat in LifeCell’s expedition to take genome sequencing to the next level in India
Subscribe To Our Newsletter & Stay Updated
